CURACLE Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
CURACLE Co., Ltd. - overview
Established
2016
Location
Seongnam, Gyeonggi-do, South Korea
Primary Industry
Biotechnology
About
Based in Seongnam-si, South Korea, and founded in 2016, CURACLE Co. , Ltd. is a biotechnology company that develops platform technology and pipelines for vascular, metabolic, immunological diseases, and cancer. Since its foundation, CURACLE Co.
, Ltd. has completed phase 2 clinical trial of CU01, a treatment for macular degeneration, and CU03, a treatment for renal fibrosis. The current CEOs of the company are Myung-Hwa Kim and Gwang-Lak Park. CURACLE Co.
, Ltd. develops pipelines using its own platform technology. CURACLE Co. , Ltd.
key pipelines include CU03 and CU06 that are used to treat age-related vascular disease, CU01 and CU02 for intractable metabolic disease, and CU04 and CU05 for cancer targeting/immunotherapy. For its future growth plans, CURACLE Co. , Ltd. plans to license out and co-develop with domestic and foreign pharmaceutical companies.
The company also plans to establish a second laboratory for toxicity and efficacy evaluation.
Current Investors
Hyundai Venture Investment , KDB Capital, Shinhan Capital
Primary Industry
Biotechnology
Sub Industries
Biotechnology
Website
www.curacle.com/en/
Company Stage
Mature
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.